A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to assess efficacy and tolerability of combination therapy
FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic
colorectal cancer.